Astellas Pharma to Acquire Iveric Bio for US$5.9 B
By Ayush Saxena
Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)
Published: 10 May-2023
DOI: 10.3833/pdr.v2023.i5.2781 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a bid to bolster its ophthalmology portfolio, Astellas has agreed to acquire Iveric Biofor US$40 per share in cash, representing a total equity value of approximately US$5...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS